Vol 15, No 3 (2019)
Other materials agreed with the Editors
Published online: 2019-06-26
Page views 797
Article views/downloads 438
Get Citation

Connect on Social Media

Connect on Social Media

Current literature review

Maciej Kawecki
Oncol Clin Pract 2019;15(3):190-193.

Abstract

Not available

Article available in PDF format

Purchase Subscription

References

  1. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817–1825.
  2. Dahan L, Phelip J, Malicot KLe, et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). Journal of Clinical Oncology. 2018; 36(15_suppl): 4000.
  3. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline-mutated metastatic pancreatic cancer. N Engl J Med. 2019 [Epub ahead of print].
  4. Hall P, Swinson D, Waters J, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. Journal of Clinical Oncology. 2019; 37(15_suppl): 4006.
  5. Buckner J, Shaw E, Pugh S, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. New England Journal of Medicine. 2016; 374(14): 1344–1355.
  6. Bell E, Won M, Fleming J, et al. Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802. J Clin Oncol. 2019; 37(15_suppl): 2002.